Abstract As a prevalent comorbidity in schizophrenia, metabolic syndrome (MetS) exerts complex influences on residual symptoms and therapeutic outcomes of antipsychotic treatment. This study investigates the underlying neuroimaging, physiological and genetic mechanisms. At baseline, 142 participants were categorized into four groups according to diagnoses of schizophrenia and MetS.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile